# Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

> **NCT06241469** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wu Jun** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Cancer
- GastroEsophageal Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** Sintilimab,nab-paclitaxel and tegio

## Key facts

- **NCT ID:** NCT06241469
- **Lead sponsor:** Wu Jun
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-03
- **Primary completion:** 2026-08-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241469, "Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06241469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*